ArticleHepatology communications2019
Lipocalin-2 Protects Against Diet-Induced Nonalcoholic Fatty Liver Disease by Targeting Hepatocytes.
Article in Hepatology communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- Microbiotas from extremely preterm infants with growth faltering impair postnatal growth and metabolism in mice.JCI insight · 2026Article
- Inflammatory Adipokines and Potential Oxidative Stress-Related Mechanisms Linking MASLD with Subclinical Atherosclerosis Within CKM Syndrome: A Systematic Review and Meta-Analysis.Antioxidants (Basel, Switzerland) · 2026Review
- SIRT1-mediated FABP4 destabilization attenuates fibrosis and ferroptosis in non-alcoholic fatty liver disease.Clinical and experimental medicine · 2026Article
- N-acetylcysteine modulates neutrophil-driven immune and metabolic pathways in steatotic liver ischemia-reperfusion injury.Frontiers in immunology · 2026Article
- Emerging roles of lipocalin-2-mediated neuroimmune interactions in chronic pain and itch.Frontiers in pharmacology · 2026Review
- Neutrophils in MASLD and MASH.BMB reports · 2025Review
- Atf3-mediated metabolic reprogramming in hepatic macrophage orchestrates metabolic dysfunction-associated steatohepatitis.Science advances · 2024Article
- Loss of SREBP-1c ameliorates iron-induced liver fibrosis by decreasing lipocalin-2.Experimental & molecular medicine · 2024Article
- Lipocalin 2-A bone-derived anorexigenic and β-cell promoting signal: From mice to humans.Journal of diabetes · 2024Review
- Time-of-day defines NADNature communications · 2023Article
- Long non-coding RNA G23Rik attenuates fasting-induced lipid accumulation in mouse liver.Molecular and cellular endocrinology · 2022Article
- Loss of FOCAD, operating via the SKI messenger RNA surveillance pathway, causes a pediatric syndrome with liver cirrhosis.Nature genetics · 2022Article
- The relationship between Lipocalin-2 level and hepatic steatosis in obese patients with NAFLD after bariatric surgery.Lipids in health and disease · 2022Observational
- The effect of lipocalin-2 (LCN2) on apoptosis: a proteomics analysis study in an LCN2 deficient mouse model.BMC genomics · 2021Article
- A Scoping Review on Lipocalin-2 and Its Role in Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma.International journal of molecular sciences · 2021Article
- Hepatocyte-specific expression of human carboxylesterase 2 attenuates nonalcoholic steatohepatitis in mice.American journal of physiology. Gastrointestinal and liver physiology · 2021Article
- Hepatocyte ATF3 protects against atherosclerosis by regulating HDL and bile acid metabolism.Nature metabolism · 2021Article
- Microbial and metabolic impacts of trehalose and trehalose analogues.Gut microbes · 2020Article
- Chronic Carbon Tetrachloride Applications Induced Hepatocyte Apoptosis in Lipocalin 2 Null Mice Through Endoplasmic Reticulum Stress and Unfolded Protein Response.International journal of molecular sciences · 2020Article
- Hepatocyte-Specific Expression of Human Carboxylesterase 1 Attenuates Diet-Induced Steatohepatitis and Hyperlipidemia in Mice.Hepatology communications · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Hepatocytes are the major source of hepatic lipocalin-2 (LCN2), which is up-regulated in response to inflammation, injury, or metabolic stress. So far, the role of hepatocyte-derived LCN2 in the development of nonalcoholic fatty liver disease (NAFLD) remains unknown. Herein we show that overexpression of human LCN2 in hepatocytes protects against high fat/high cholesterol/high fructose (HFCF) diet-induced liver steatosis and nonalcoholic steatohepatitis by promoting lipolysis and fatty acid oxidation (FAO) and inhibiting
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.